http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2696782-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8524b34ba744143e99751920ee49ba4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 |
| filingDate | 2018-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e78abc38f0c425770aa5ba5cf5d0ecb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_269bdf69e0efbb0fb73c10d3494b9f14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22ca185c78e1ed1ad81860e1dc624105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87b042ecd3e14ee0094220050661aa57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccbe898fdf51eb1a320601e1e4c8e166 |
| publicationDate | 2019-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2696782-C1 |
| titleOfInvention | Method of relieving resistant depressive syndromes of psychosomatic circle |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to psychiatry, and concerns the management of resistant depressive psychosomatic syndromes. That is ensured by parenteral introduction of tricyclic antidepressants combined with neuroleptics. Combination is obtained by mixing in 200 ml of physiologic saline successively 2.0–6.0 ml of 1.25 % clomipramine (anaphranil) and 1.0–2.0 ml of 0.2 % trifluoperazine (triftazine) solution. Administration is performed intravenously for 1.5–2 hours with control of arterial pressure and pulse every 30 minutes, followed by rest for 30–40 minutes, course of treating 12–14 infusions. That is followed by a strategic maintenance pathogenetic therapy for 6 months with the oral administration of clomipramine (anaphranil) in dose of 50–75 mg in a combination with trifluoperazine (triftazine) in dose of 2.5–5 mg.EFFECT: introduction of such combination of medicinal preparations in the specified mode provides fast overcoming of therapeutic resistance in the given group of patients with minimum by-effects.1 cl, 3 ex |
| priorityDate | 2018-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.